Dad releases music in honour of âthoughtful and brightâ son, 7, who died from brain tumour
Chris Nelson is hoping to raise money for two cancer organisations with new music released in honour of son Blaise, who died in 2019
Updated
Don t miss a thing by getting the latest from the Manchester Evening News sent
direct to your inboxInvalid EmailSomething went wrong, please try again later.
Click here
When you subscribe we will use the information you provide to send you these newsletters. Sometimes theyâll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
Unlike MRI scans – the gold-standard for cancer detection – sheer wave scans can be carried out in theatre, with the information passed immediately to the surgeon to enable the removal of residual cancerous tissue without additional surgeries. In a study published in
Frontiers in Oncology, it was found the technique outperformed surgeons at detecting leftover cancerous tissue by sight alone, and could prove to be a vital technology in improving outcomes for brain tumour patients.
“Ensuring all of a brain tumour is removed without damaging healthy tissue is a major challenge in brain surgery,” said study lead Professor Jeffrey Bamber, Professor in Physics Applied to Medicine at The Institute of Cancer Research, London. “Using this new type of scan, surgeons could greatly increase confidence that no cancerous tissue is going to be left behind after surgery.”
A type of ultrasound scan can detect cancer tissue left behind after a brain tumour is removed more sensitively than surgeons, and could improve the outcome from operations, a new study suggests.
A type of ultrasound scan can detect cancer tissue left behind after a brain tumor is removed more sensitively than surgeons, and could improve the outcome from operations, a new study suggests.
Blood test picks out prostate cancer drug resistance 04
Blood test picks out prostate cancer drug resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
The new research paves the way for information from a blood test to inform prostate cancer treatment in future, with only those patients whose cancers are free of resistance mutations taking the drug, abiraterone.
The study is also a proof of principle that tests for cancer DNA in the bloodstream can be used to detect drug resistance mutations – allowing patients who will not benefit from one drug to be given an alternative treatment instead.